# Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)

Study · id `cardio:ct-nct07653477` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07653477](<https://clinicaltrials.gov/study/NCT07653477>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07653477

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 956 participants.

## Technical summary

Registry record NCT07653477. Randomized; no masking; primary purpose treatment. Start 2026-09-07 (actual); primary completion 2028-02-29 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 956 participants (planned count; ClinicalTrials.gov record NCT07653477, source copy `cardio:ctgov-nct07653477-2026-09-14`, retrieved 2026-10-26)
- Started: 2026-09-07 (actual) (ClinicalTrials.gov record NCT07653477, source copy `cardio:ctgov-nct07653477-2026-09-14`, retrieved 2026-10-26)
- Primary completion: 2028-02-29 (anticipated) (ClinicalTrials.gov record NCT07653477, source copy `cardio:ctgov-nct07653477-2026-09-14`, retrieved 2026-10-26)
- Completion: 2028-02-29 (anticipated) (ClinicalTrials.gov record NCT07653477, source copy `cardio:ctgov-nct07653477-2026-09-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07653477, source copy `cardio:ctgov-nct07653477-2026-09-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07653477-2026-09-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
- Acronym: UNIGUIDE-2
- Condition: Type 2 Diabetes
- Intervention (Drug): UBT251 Injection 2.0 mg group
- Intervention (Drug): UBT251 Injection 4.0 mg group
- Intervention (Drug): UBT251 Injection 6.0 mg group
- Intervention (Drug): Semaglutide Injection
- Lead sponsor: The United Bio-Technology (Hengqin) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: The United Bio-Technology (Hengqin) Co., Ltd. (`cardio:org-the-united-bio-technology-hengqin-co-ltd`)

## Provenance

Content hash: 4bff62d8281c6fccb1b67f3365aaa6b0f25d5c05bf43fea1c6c4f8e3c10c2aa5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
